CCM
LXRX icon

Coldstream Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Coldstream Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,388
Closed -$640 – 2368
2025
Q1 		$640 Buy
+1,388
New +$876 ﹤0.01% 3287

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Coldstream Capital Management's LXRX Position: Q2 2025 in Review

Coldstream Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2025, closing a stake of 1,388 shares — an estimated $640 sold.

Coldstream Capital Management first reported a position in LXRX in Q1 2025 and held it in 1 quarter. The position peaked at $640 in Q1 2025. 123 funds tracked by Wall St. Rank hold LXRX as of Q2 2025.

  • Coldstream Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 1,388 Lexicon Pharmaceuticals shares in Q2 2025, an estimated $640.
  • Coldstream Capital Management first reported a position in Lexicon Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Lexicon Pharmaceuticals position peaked at $640 in Q1 2025.
  • 123 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.